Commentary to ‘Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population’

Journal of Medical Ethics 47 (9):617-617 (2021)
  Copy   BIBTEX

Abstract

The article by Gustavsson et al 1 addresses the important question how to handle new medications with focus on drug candidates that reduce Aβ or tau in the brain, for individuals with Alzheimer’s disease, where the need for a disease-modifying drug is enormous. There are several ethical issues to deal with. The challenges and ethical implications associated with whom should be eligible for treatment are thoroughly discussed in the article. Should treatment only be available to those with mild symptoms and/or to those with no symptoms but with risk for AD? Where do we draw the line between who will be eligible for treatment and who will not? Who will be responsible for the prioritisation? There are many ethical problems with both population screening and screening of those with high risk well discussed in the article. Indeed, the first immunotherapy drug Aducanumab was approved by the US Food and Drug Administration in …

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 90,616

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Cognitive Aging: What We Fear and What We Know.I. I. Dan G. Blazer - 2018 - Perspectives in Biology and Medicine 60 (4):569-582.
The burden of dementia: A medical and research perspective.Piero Antuono & Jan Beyer - 1999 - Theoretical Medicine and Bioethics 20 (1):3-13.
Alzheimer's Disease: Disruption of Mind-Brain Relations.S. I. Rapoport - 1992 - In Y. Christen & P. S. Churchland (eds.), Neurophilosophy and Alzheimer's Disease. Springer Verlag. pp. 86--107.
Commentary.Robert Gatter - 1999 - Cambridge Quarterly of Healthcare Ethics 8 (3):377-378.
Consciousness: Evidence of Four Components in Alzheimer's Disease.J. L. Signoret - 1992 - In Y. Christen & P. S. Churchland (eds.), Neurophilosophy and Alzheimer's Disease. Springer Verlag. pp. 144--150.

Analytics

Added to PP
2021-08-23

Downloads
8 (#1,138,679)

6 months
3 (#447,120)

Historical graph of downloads
How can I increase my downloads?